A comparison of antiasthma drugs between acute and chronic ovalbumin-challenged guinea-pig models of asthma

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 6, 2012, Pages 453-464

  Evans, Rhys L ^a   Nials, Anthony T ^b   Knowles, Richard G ^b   Kidd, Emma J ^a   Ford, William R ^a   Broadley, Kenneth J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Airways hyperresponsiveness; Chronic guinea pig asthma models; Early and late asthmatic responses; Fluticasone propionate; GW274150; Remodelling; Roflumilast

Indexed keywords

COLLAGEN; FLUTICASONE PROPIONATE; HISTAMINE; OVALBUMIN; ROFLUMILAST; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE;

AIRWAY CONDUCTANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHOSPASM; CELL HYPERPLASIA; CHRONIC INFLAMMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EOSINOPHIL; EXPERIMENTAL GUINEA PIG; EXPERIMENTAL MODEL; GOBLET CELL; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; INHALATION TEST; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG PARENCHYMA; MALE; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; SENSITIZATION; TREATMENT RESPONSE;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AMINOPYRIDINES; ANDROSTADIENES; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BENZAMIDES; BRONCHIAL HYPERREACTIVITY; CHRONIC DISEASE; CYCLOPROPANES; DISEASE MODELS, ANIMAL; GUINEA PIGS; HISTAMINE; INFLAMMATION; MALE; OVALBUMIN; SULFIDES; TIME FACTORS;

EID: 84870236442     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.08.004     Document Type: Article

References (46)

1. McMillan S.J., Lloyd C.M. Prolonged allergen challenge in mice leads to persistent airway remodeling. Clin Exp Allergy 2004, 34:497-507.
2. Wegmann M., Fehrenbach H., Fehrenbach A., Held T., Schramm C., Garn H., et al. Involvement of distal airways in a chronic model of experimental asthma. Clin Exp Allergy 2005, 35:1263-1271.
3. Di Valentin E., Crahay C., Garbacki N., Hennuy B., Gueders M., Noel A., et al. New asthma biomarkers: lessons from murine models of acute and chronic asthma. Am J Physiol Lung Cell Mol Physiol 2009, 296:L185-L197.
4. Riesenfeld E.P., Sullivan M.J., Thompson-Figueroa J.A., Haverkamp H.C., Lundblad L.K., Bates J.H., et al. Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease. Respir Res 2010, 11:22.
5. Hoymann H.G., Wollin L., Muller M., Korolewitz R., Krug N., Braun A., et al. Effects of the phosphodiesterase type 4 inhibitor roflumilast on early and late allergic response and airway hyperresponsiveness in Aspergillus-fumigatus-sensitized mice. Pharmacology 2009, 83:188-195.
6. Kumar R.K., Herbert C., Thomas P.S., Wollin L., Beume R., Yang M., et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther 2003, 307:349-355.
7. Canning B.J., Chou Y. Using guinea pigs in studies relevant to asthma and COPD. Pulm Pharmacol Ther 2008, 21:702-720.
8. Ricciardolo F.L., Nijkamp F., De Rose V., Folkerts G. The guinea pig as an animal model for asthma. Curr Drug Targets 2008, 9:452-465.
9. Zosky G.R., Sly P.D. Animal models of asthma. Clin Exp Allergy 2007, 37:973-988.
10. Bos I.S., Gosens R., Zuidhof A.B., Schaafsma D., Halayko A.J., Meurs H., et al. Inhibition of allergen-induced airway remodeling by tiotropium and budesonide: a comparison. Eur Respir J 2007, 30:653-661.
11. Maarsingh H., Dekkers B.G., Zuidhof A.B., Bos I.S., Menzen M.H., Klein T., et al. Increased arginase activity contributes to airway remodeling in chronic asthma. Eur Repir J 2011, 38:318-328.
12. Starling C.M., Prado C.M., Leick-Maldonado E.A., Lanças T., Reis F.G., Aristoteles L.R., et al. Inducible nitric oxide synthesase inhibition attenuates lung tissue responsiveness and remodeling in a model of chronic pulmonary inflammation in guinea pigs. Respir Physiol Neurobiol 2009, 165:185-194.
13. Angeli P., Prado C.M., Xisto D.G., Silva P.L., Passaro C.P., Nakazato H.D., et al. Effects of chronic L-NAME treatment on lung tissue mechanics, eosinophilic and extracellular matrix responses induced by chronic pulmonary inflammation. Am J Physiol Lung Cell Mol Physiol 2008, 294:L1197-L1205.
14. Bazan-Perkins B., Sanchez-Guerrero E., Vargas M.H., Martinez-Cordero E., Ramos-Ramirez P., Alvarez-Santos M., et al. Beta1-integrins shedding in a guinea-pig model of chronic asthma with remodelled airways. Clin Exp Allergy 2009, 39:740-751.
15. Smith N., Broadley K.J. Optimisation of the sensitisation conditions for an ovalbumin challenge model of asthma. Int Immunopharmacol 2007, 7:183-190.
16. Palmqvist M., Bruce C., Sjostrand M., Arvidsson P., Lotvall J. Differential effects of fluticasone and montelukast on allergen-induced asthma. Allergy 2005, 60:65-70.
17. Feltis B.N., Wignarajah D., Reid D.W., Ward C., Harding R., Walters E.H. Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma. Thorax 2007, 62:314-319.
18. Louw C., Williams Z., Venter L., Leichtl S., Schmid-Wirlitsch C., Bredenbroker D., et al. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration 2007, 74:411-417.
19. van Schalkwyk E., Strydom K., Williams Z., Venter L., Leichtl S., Schmid-Wirlitsch C., et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005, 116:292-298.
20. Knowles R.G., Salmon M., Kurusu O., Kilian D., Hurle M., Ozawa K., et al. Anti-inflammatory profile of the highly-selective iNOS inhibitor GW274150 in animal models of lung disease. Proc Am Thorac Soc 2007, 4:A487.
21. Singh D., Richards D., Knowles R.G., Schwartz S., Woodcock A., Langley S., et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med 2007, 176:988-993.
22. O'Byrne P.M., Gauvreau G.M., Brannan J.D. Provoked models of asthma: what have we learnt?. Clin Exp Allergy 2009, 39:181-192.
23. Kumar R.K., Foster P.S. Modeling allergic asthma in mice: pitfalls and opportunities. Am J Respir Cell Mol Biol 2002, 27:267-272.
24. Krug N., Rabe K.F. Animal models for asthma: the perspective of a clinician. Curr Drug Targets 2008, 9:438-442.
25. Diaz P., Gonzalez M.C., Galleguillos F.R., Ancic P., Cromwell O., Shepherd D., et al. Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions. Am Rev Respir Dis 1989, 139:1383-1389.
26. Hutson P.A., Varley J.G., Sanjar S., Kings M., Holgate S.T., Church M.K. Evidence that neutrophils do not participate in the late-phase airway response provoked by ovalbumin inhalation in conscious, sensitized guinea pigs. Am Rev Respir Dis 1990, 141:535-539.
27. Toward T.J., Broadley K.J. Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram. Clin Exp Allergy 2004, 34:91-102.
28. Kenyon N.J., Last J.A. Reversible and irreversible airway inflammation and fibrosis in mice exposed to inhaled ovalbumin. Inflamm Res 2005, 54:57-65.
29. Lawrence T.E., Millecchia L.L., Fedan J.S. Fluticasone propionate and pentamidine isethionate reduce airway hyperreactivity, pulmonary eosinophilia and pulmonary dendritic cell response in a guinea pig model of asthma. J Pharmacol Exp Ther 1998, 284:222-227.
30. Bradley B.L., Azzawi M., Jacobson M., Assoufi B., Collins J.V., Irani A.M., et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991, 88:661-674.
31. Chapoval S.P., Nabozny G.H., Marietta E.V., Raymond E.L., Krco C.J., Andrews A.G., et al. Short ragweed allergen induces eosinophilic lung disease in HLA-DQ transgenic mice. J Clin Invest 1999, 103:1707-1717.
32. Barnes P.J. Corticosteroid effects on cell signalling. Eur Respir J 2006, 27:413-426.
33. Rogers D.F. Airway mucus hypersecretion in asthma: an undervalued pathology. Curr Opin Pharmacol 2004, 4:241-250.
34. Kai S., Nomura A., Morishima Y., Ishii Y., Sakamoto T., Kiwamoto T., et al. Effect of inhaled steroids on increased collagen synthesis in asthma. Respiration 2007, 74:154-158.
35. Bousquet J.B., Jeffery P.K., Busse W.W., Johnson M., Vignola A.M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000, 161:1720-1745.
36. Schramm C.M., Grunstein M.M. Assessment of signal transduction mechanisms regulating airway smooth muscle contractility. Am J Physiol 1992, 262(2 Pt 1):L119-L139.
37. Bundschuh D.S., Eltze M., Barsig J., Wollin L., Hatzelmann A., Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001, 297:280-290.
38. Nejman-Gryz P., Grubek-Jaworska H., Glapinski J., Hoser G., Chazan R. Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma. J Physiol Pharmacol 2006, 57(Suppl 4):229-239.
39. Deng Y.M., Xie Q.M., Tang H.F., Sun J.G., Deng J.F., Chen J.Q., et al. Effects of ciclamilast, a new PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. Eur J Pharmacol 2006, 547:125-135.
40. Burgess J.K., Oliver B.G., Poniris M.H., Ge Q., Boustany S., Cox N., et al. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. J Allergy Clin Immunol 2006, 118:649-657.
41. Mata M., Sarria B., Buenestado A., Cortijo J., Cerda M., Morcillo E.J. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005, 60:144-152.
42. Durrani S.R., Viswanathan R.K., Busse W.W. What effect does asthma treatment have on airway remodeling? Current perpectives. J Allergy Clin Immunol 2011, 128:439-448.
43. Nevin B.J., Broadley K.J. Nitric oxide in respiratory diseases. Pharmacol Ther 2002, 95:259-293.
44. Kenyon N.J., Gohil K., Last J.A. Susceptibility to ovalbumin-induced airway inflammation and fibrosis in inducible nitric oxide synthetase-deficient mice: mechanisms and consequences. Toxicol Appl Pharmacol 2003, 191:2-11.
45. Johnson J.R., Wiley R.E., Fattouh R., Swirshi F.K., Gajewska B.U., Coyle A.J., et al. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. Am J Respir Crit Care Med 2004, 169:378-385.
46. De Alba J., Raemdonck K., Dekkak A., Collins M., Wong S., Nials A.T., et al. House dust mite induces direct airway inflammation in vivo: implications for future disease therapy?. Eur Respir J 2009, 35:1377-1387.